网站主页 >> CAS数据库列表 >> 4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐
4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐
|
|
|
- CAS号:
- 1345614-59-6
- 英文名:
- AM-095
- 英文别名:
- AM-095;AM095 sodium;AM095 >=98% (HPLC);AM095 (Sodium Salt);AM-095;AM095;AM 095;AM095 hydrochloride;LPL Receptor,AM095,inhibit,Lysophospholipid Receptor,Inhibitor,AM-095,AM 095;sodium,2-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetate;(2-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetic acid) sodium salt;4'-[3-Methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl]-[1,1'-biphenyl]-4-acetic acid sodium salt (1:1)
- 中文名:
- 4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐
- 中文别名:
- 化合物AM095;AM095, LPA1 受体拮抗剂;4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐;4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐
- CBNumber:
- CB52627312
- 分子式:
- C27H25N2NaO5
- 分子量:
- 480.5
- MOL File:
- 1345614-59-6.mol
|
|
|
4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐化学性质
-
储存条件:
-
room temp
-
|
-
溶解度:
-
≥23.9 mg/mL in DMSO; insoluble in H2O; ≥16.77 mg/mL in EtOH with ultrasonic
-
|
-
形态:
-
powder
-
|
-
颜色:
-
white to beige
-
|
4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐性质、用途与生产工艺
AM095 是一种选择性的 LPA1 受体拮抗剂。作用于人和鼠 转染 LPA1 的 CHO 细胞，AM095 拮抗 LPA 诱导的钙流动，IC50 分别为 0.025 和 0.023 μM。
AM095 is a potent LPA
1
receptor antagonist because it inhibits GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA
1
with IC
50
values of 0.98 and 0.73 μM, respectively. AM095 inhibits LPA-driven chemotaxis of CHO cells overexpressing mouse LPA
1
(IC
50
=778 nM) and human A2058 melanoma cells (IC
50
=233 nM). The IC
50
of AM095 in the human LPA
1
GTPγS binding assay is comparable with that of our previously published compound AM966 (IC
50
=0.98±0.17 μM) and the Debio-0719 compound (IC
50
=0.60±0.04 μM). AM095 inhibits the LPA-induced calcium flux of CHO cells stably transfected with human or mouse LPA
1
. The IC
50
for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA
1
-transfected CHO cells is 0.025 and 0.023 μM, respectively.
AM095 has high oral bioavailability and a moderate half-life and is well tolerated at the doses tested in rats and dogs after oral and intravenous dosing. After oral (10 mg/kg) dosing in rats, AM095 plasma concentrations peaked at 2 h with a C
max
of 41 μM, thereafter decreasing to 10 nM by 24 h. After intravenous (2 mg/kg) dosing, a C
max
of 12 μM is observed within 15 min, which also decreased to approximately 10 nM by 24 h, yielding a t
1/2
of 1.79 h. In dogs, a single oral dose of 5 mg/kg yielded a peak plasma concentration of 21 μM within 15 min of dosing, which then decreased to 10 nM by 24 h. In contrast, an intravenous dose of 2 mg/kg resulted in a C
max
of 11 μM within 15 min and decreased to 15 nM by 8 h, yielding a t
1/2
of 1.5 h.
4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-16039 | AM095 | | 1 mg | 659元 |
| 2024/04/30 | HY-16039 | 4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐
AM095 | 1345614-59-6 | 5mg | 1450元 |
4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐
生产厂家
1345614-59-6, 4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐 相关搜索:
- Inhibitors
- 药靶配体
- 精细化工产品
- 小分子抑制剂，天然产物
- 小分子抑制剂
- LPA抑制剂分子
- G蛋白偶联受体&G蛋白
- C27H23N2NaO5
- C27H23N2O5Na
- C27H24N2O5Na
- 4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐
- AM095, LPA1 受体拮抗剂
- 化合物AM095
- 4'-[3-甲基-4-[[[(1R)-1-苯基乙氧基]羰基]氨基]-5-异恶唑基]联苯-4-乙酸钠盐
- 1345614-59-6
- LPL Receptor,AM095,inhibit,Lysophospholipid Receptor,Inhibitor,AM-095,AM 095
- AM-095;AM095;AM 095
- AM095 hydrochloride
- (2-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetic acid) sodium salt
- sodium,2-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetate
- AM095 sodium
- AM095 >=98% (HPLC)
- AM095 (Sodium Salt)
- 4'-[3-Methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl]-[1,1'-biphenyl]-4-acetic acid sodium salt (1:1)
- AM-095